TLR2 and neoplasm: To further explore whether dual TLR2 agonist and GM-CSF stimulation effectively treated diverse syngeneic tumor models, we leveraged OVA as the tumor antigen to investigate TLR2 agonist and GM-CSF therapeutic effects on T cell thymoma (E.G7-OVA) and melanoma (B16F10-OVA), which represent aggressive and metastatic tumor models, respectively.